What is the optimal (neo)adjuvant strategy of extremity high-risk soft tissue sarcomas (ESTS)?

Elena Palassini, Sara Pizzamiglio, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martín‐Broto, Giovanni Grignani, Antonella Brunello, Jean Yves Blay, Oscar Tendero, Robbie Beveridge, Antonio López–Pousa, Virginia Ferraresi, Iwona Ługowska, Valeria Fontana, Giuseppe Bianchi, Silvia Stacchiotti, Angelo Paolo Dei Tos, Paolo Verderio, Paolo G. Casali, Alessandro Gronchi

What is the optimal (neo)adjuvant strategy of extremity high-risk soft tissue sarcomas (ESTS)?

Discussion(0)

Related publications

Isolated limb infusion for the treatment of advanced extremity soft tissue sarcomas

Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas

Menstrual and reproductive factors and risk of soft tissue sarcomas

Diet and risk of lymphoid neoplasms and soft tissue sarcomas

A phase III randomized trial of neo-adjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STS 1001): Feasibility and activity of concurrent chemotherapy and radiation therapy.